Odyssean LLC Makes New $1.24 Million Investment in Corcept Therapeutics Incorporated $CORT

Posted by Geri Gentry on Aug 26th, 2026

Odyssean LLC purchased a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,271 shares of the biotechnology company’s stock, valued at approximately $1,241,000.

A number of other large investors have also recently modified their holdings of the business. Torren Management LLC purchased a new position in shares of Corcept Therapeutics during the fourth quarter worth about $25,000. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics in the third quarter valued at approximately $25,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Corcept Therapeutics during the second quarter valued at approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in Corcept Therapeutics during the fourth quarter valued at approximately $31,000. Finally, State of Wyoming lifted its holdings in shares of Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 186 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on CORT. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. Weiss Ratings upgraded Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 20th. UBS Group set a $135.00 price objective on Corcept Therapeutics in a research report on Thursday, May 28th. Finally, Piper Sandler reissued an “overweight” rating and set a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $138.17.

View Our Latest Stock Report on CORT

Insider Buying and Selling

In other news, insider Sean Maduck sold 25,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $88.35, for a total value of $2,208,750.00. Following the completion of the sale, the insider owned 9,755 shares of the company’s stock, valued at approximately $861,854.25. The trade was a 71.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Atabak Mokari sold 80,000 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $114.71, for a total value of $9,176,800.00. Following the completion of the sale, the chief financial officer directly owned 16,130 shares of the company’s stock, valued at approximately $1,850,272.30. This trade represents a 83.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 440,146 shares of company stock worth $43,659,514 in the last ninety days. Corporate insiders own 20.70% of the company’s stock.

Corcept Therapeutics Stock Performance

Shares of Corcept Therapeutics stock opened at $123.57 on Wednesday. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $126.38. The company has a fifty day moving average of $98.99 and a 200-day moving average of $65.93. The stock has a market capitalization of $13.36 billion, a price-to-earnings ratio of 294.22 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The company had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. During the same quarter last year, the company earned $0.29 EPS. The firm’s revenue was up 31.7% compared to the same quarter last year. On average, equities research analysts forecast that Corcept Therapeutics Incorporated will post 1.77 earnings per share for the current fiscal year.

About Corcept Therapeutics

(Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.